Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02785900 · ClinicalTrials.gov registry record · Phase 3
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 3 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT02785900: Clinical Trial Phase 3 study, sponsored by Seagen.
NCT02785900 is a Phase 3 study that was terminated before completion, run by Seagen. The registered enrollment target is 240 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02785900, a Phase 3 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine improves remission rates and extends overall survival as compared to placebo combined with either azacitidine or decitabine.
Primary Outcome
Time from randomization to death due to any cause
Interventions
- DRUG placebo
- DRUG azacitidine
- DRUG decitabine
- DRUG 33A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-10-03 |
| Phase | Phase 3 |
Why NCT02785900 stopped before completion
NCT02785900 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT02785900 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02785900 about?
NCT02785900 is a clinical study titled "Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia". The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine improves remission rates and extends overall survival as compared to placebo combined with either azacitidine or decitabine.
What is the current status of trial NCT02785900?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2016-05. Estimated completion is 2017-10-03.
What interventions are being tested in trial NCT02785900?
The interventions under investigation include: placebo (DRUG), azacitidine (DRUG), decitabine (DRUG), 33A (DRUG).
Who is sponsoring clinical trial NCT02785900?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02785900's enrollment target sits among peer trials
240 1273rd of 2000 higher than 710 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia